In one study, reporting on 42 patients with SM, TET2 mutations were not found to alter the prognosis of the disease [4], whereas two other studies showed that the presence of TET2 mutations conferred a poor prognosis to patients with aggressive SM [5], [7]. The gene discussed is TET2; the disease is systemic mastocytosis.